Dan

Data continues to demonstrate the broader potential of ‘1104 to avoid and reduce inflammation in multiple models of disease, including allergy and beyond NEW ORLEANS and CAMBRIDGE, UK, May 22, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with […]

NEW ORLEANS and CAMBRIDGE, UK, May 10, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will present at two medical meetings in May: the American Thoracic Society (ATS) International Conference

– Data shows achievement of primary endpoint of decreasing esophageal intraepithelial eosinophil count and positive impact on an array of histological measures of EoE – – Favorable safety and tolerability profile consistent with Phase 1 trial results – NEW ORLEANS and CAMBRIDGE, UK, April 19 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company

NEW ORLEANS, LA and CAMBRIDGE, England, April 13, 2023 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that management will be presenting at the 8th Food Allergy Fund Summit being held on

Study data anticipated in Q2 2023 NEW ORLEANS, LA and CAMBRIDGE, England, March 27, 2023 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the last patient has completed the twelve-week Phase

Data demonstrates the potential of ‘1104 as an allergen-agnostic therapeutic for the treatment of food allergy NEW ORLEANS, LA and CAMBRIDGE, England, February 28, 2023 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today

NEW ORLEANS and LONDON, February 6, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that recently generated preclinical data for ‘1104 in Food Allergy will be presented at the 2023 American Academy

NEW ORLEANS, LA and LONDON, UK, November 14, 2022 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the TIDES Europe 2022 Conference on Oligonucleotide & Peptide Therapeutics,

Topline data anticipated in early 2023 NEW ORLEANS, LA and LONDON, UK, November 9, 2022 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the last patient has completed a Phase 2a proof